Matthew Barcus
Stock Analyst at Chardan Capital
(2.47)
# 2,465
Out of 5,056 analysts
21
Total ratings
25%
Success rate
29.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $3.83 | +161.10% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $29.71 | -9.12% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.75 | +833.33% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $23.69 | +35.08% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $0.80 | +27,365.67% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $4.10 | +119.51% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $17.86 | -55.21% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $3.83
Upside: +161.10%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $29.71
Upside: -9.12%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.75
Upside: +833.33%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $23.69
Upside: +35.08%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $0.80
Upside: +27,365.67%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $4.10
Upside: +119.51%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $17.86
Upside: -55.21%